Solana (NASDAQ:HSDT) Releases Quarterly Earnings Results, Misses Estimates By $0.96 EPS

Solana (NASDAQ:HSDT) posted its earnings results on Friday. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.96), FiscalAI reports. The company had revenue of $3.62 million for the quarter, compared to analyst estimates of $3.40 million. Solana had a negative return on equity of 104.96% and a negative net margin of 679.54%.

Here are the key takeaways from Solana’s conference call:

• Solana Company said first-quarter revenue rose to $3.6 million from just $49,000 a year ago, driven mainly by $3.4 million of staking revenue. Management framed this as early validation of its digital asset treasury strategy.
• The company reported a net loss of $99.8 million, largely due to non-cash markdowns tied to the roughly 33% decline in SOL during the quarter. It also recorded an $89.2 million unrealized loss on digital assets and receivables.
• Management highlighted 6.9% average net staking yield in Q1, above the estimated system-wide average of about 6.0%. They said this outperformance came from validator selection, MEV capture, and active rebalancing.
• The company completed an $8 million strategic equity raise in late April at a price described as about 1.1x NAV, and said part of the proceeds was used to buy SOL at attractive levels. Management called the raise immediately accretive to SOL per share.
• Solana Company is expanding beyond treasury management into advisory services, validator infrastructure, and an AI-powered platform, with initial validator nodes expected to go live in late June. Management also said it completed the divestiture of its medical device business, which should help reduce future costs.

Solana Stock Down 3.8%

Shares of HSDT traded down $0.09 on Friday, hitting $2.30. The company’s stock had a trading volume of 147,829 shares, compared to its average volume of 216,834. The firm’s fifty day moving average price is $2.06 and its 200-day moving average price is $2.92. Solana has a fifty-two week low of $1.59 and a fifty-two week high of $258.50. The firm has a market capitalization of $126.25 million, a price-to-earnings ratio of 0.00 and a beta of 1.06.

Analyst Ratings Changes

Several equities analysts have recently issued reports on HSDT shares. Maxim Group started coverage on Solana in a research report on Monday, April 6th. They set a “buy” rating and a $4.00 target price for the company. B. Riley Financial started coverage on Solana in a research report on Thursday, April 23rd. They set a “buy” rating and a $3.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Solana in a research report on Tuesday, April 21st. Finally, Zacks Research upgraded Solana to a “hold” rating in a research report on Monday, April 27th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Solana has a consensus rating of “Moderate Buy” and an average target price of $3.50.

Hedge Funds Weigh In On Solana

Several institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd acquired a new position in shares of Solana in the 4th quarter valued at approximately $140,000. Cetera Investment Advisers acquired a new position in Solana during the 4th quarter worth approximately $347,000. Price T Rowe Associates Inc. MD acquired a new position in Solana during the 4th quarter worth approximately $46,000. OMERS ADMINISTRATION Corp acquired a new position in Solana during the 4th quarter worth approximately $88,000. Finally, Marshall Wace LLP acquired a new position in Solana during the 4th quarter worth approximately $195,000. 18.63% of the stock is currently owned by institutional investors and hedge funds.

About Solana

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.